Live-Suche
TopFind ruft die neuesten Treffer für deine Suche ab.
Wir haben 58 Live-Ergebnisse für besremi ropeginterferon alfa 2b geprüft und auf 3 Optionen eingegrenzt, die sich zuerst am meisten zum Vergleichen eignen.
Die stärksten Themen in dieser Auswahlliste sind Pharmaceuticals und Haematology.
Quelle: PharmaEssentia Singapore Pte. Ltd.
Beschreibung
Besremi is a prescription-only biological therapeutic specifically approved for the treatment of Polycythemia Vera (PV) in adults. This long-acting monopegylated interferon is delivered as a 500 micrograms/mL solution for injection in a prefilled syringe, designed for convenient administration and prolonged therapeutic effect in managing myeloproliferative neoplasms (MPN). It was officially launched in Singapore in September 2024 following approval by the Health Sciences Authority (HSA).
Am besten für
Patients with Polycythemia Vera, Long Acting interferon therapy, Specialized haematology care und Prescription biological treatments
Bewertung
Quelle: PharmaEssentia
Beschreibung
Besremi (ropeginterferon alfa-2b) is a solution for injection provided in a 500 mcg/mL pre-filled syringe. It is a monopegylated interferon specifically indicated for the treatment of adults with Polycythemia Vera (PV). It was recently registered by the Health Sciences Authority (HSA) in May 2024 and launched in Singapore in September 2024 as a new long-acting interferon option.
Am besten für
Polycythemia Vera patients, Long Acting interferon therapy, Newly registered HSA treatments und Hematology patients
Bewertung
Quelle: Centre for Clinical Haematology (CFCH)
Beschreibung
Professional medical service involving the specialist consultation, prescription, and clinical administration of Besremi (ropeginterferon alfa-2b) for the treatment of Polycythemia Vera. The service includes patient monitoring and expert management of Myeloproliferative Neoplasms (MPNs) in a clinical setting.
Am besten für
MPN patient management, Supervised biological injections, Specialist haematology advice und Private oncology care
Bewertung
| Vergleichen | Besremi (ropeginterferon alfa-2b) | Besremi | Besremi Clinical Consultation and Administration |
|---|---|---|---|
| Quelle | PharmaEssentia Singapore Pte. Ltd. | PharmaEssentia | Centre for Clinical Haematology (CFCH) |
| Beschreibung | Besremi is a prescription-only biological therapeutic specifically approved for the treatment of Polycythemia Vera (PV) in adults. This long-acting monopegylated interferon is delivered as a 500 micrograms/mL solution for injection in a prefilled syringe, designed for convenient administration and prolonged therapeutic effect in managing myeloproliferative neoplasms (MPN). It was officially launched in Singapore in September 2024 following approval by the Health Sciences Authority (HSA). | Besremi (ropeginterferon alfa-2b) is a solution for injection provided in a 500 mcg/mL pre-filled syringe. It is a monopegylated interferon specifically indicated for the treatment of adults with Polycythemia Vera (PV). It was recently registered by the Health Sciences Authority (HSA) in May 2024 and launched in Singapore in September 2024 as a new long-acting interferon option. | Professional medical service involving the specialist consultation, prescription, and clinical administration of Besremi (ropeginterferon alfa-2b) for the treatment of Polycythemia Vera. The service includes patient monitoring and expert management of Myeloproliferative Neoplasms (MPNs) in a clinical setting. |
| Am besten für | Patients with Polycythemia Vera, Long Acting interferon therapy, Specialized haematology care und Prescription biological treatments | Polycythemia Vera patients, Long Acting interferon therapy, Newly registered HSA treatments und Hematology patients | MPN patient management, Supervised biological injections, Specialist haematology advice und Private oncology care |
| Aktion | |||
| Bewertung |
Wenn du mit der ausgewogensten Option starten möchtest, empfehle ich:
"Besremi (ropeginterferon alfa-2b) von PharmaEssentia Singapore Pte. Ltd.."
Ich habe dies ausgewählt, weil As the official local subsidiary of the manufacturer, this entity provides the primary source-backed pharmaceutical supply and regulatory oversight for Besremi in Singapore.